康哲藥業(00867.HK)與全球製藥公司SPARC就創新產品簽訂許可協議
格隆匯11月5日丨康哲藥業(00867.HK)發佈公告,2019年11月5日,集團通過全資附屬公司與Sun Pharma Advanced Research Company Ltd.(“SPARC”)就其五個創新產品簽訂了許可協議。
根據協議的約定,集團通過全資附屬公司獲得了根據SPARC的知識產權和註冊文件在大中華地區(包括中國大陸、香港特別行政區、澳門特別行政區和台灣)開發與商業化產品的獨家的、可分許可的許可權利。協議的初始期間為產品在區域首次上市銷售起算二十年,在集團全資附屬公司達到協議約定的特定條件後,協議將按三年為一個區間續期。通過此次合作,集團現有的產品組合將在產品於區域上市後得以豐富及擴張。
根據披露,SPARC是一家全球製藥公司,致力於通過創新的治療和給藥方式不斷提高全球患者的護理標準。SPARC旨在不斷降低成本並提高運營效率,以提高世界各地患者對治療方法的可用性和可承受性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.